Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer presso 89BIO, INC.
Patrimonio netto: 3 M $ in data 31/03/2024
Posizioni attive di Quoc Le-Nguyen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| 89BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2019 | - |
Storia della carriera di Quoc Le-Nguyen
Precedenti posizioni note di Quoc Le-Nguyen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2015 | 01/07/2018 |
| BAYER AG | Corporate Officer/Principal | 01/09/2007 | 01/09/2013 |
Formazione di Quoc Le-Nguyen
| University of California | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Germania | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BAYER AG | Health Technology |
| 89BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Borsa valori
- Insiders
- Quoc Le-Nguyen
- Esperienza
